BioGaia starts its own distribution in the UK
Beginning in November 2021, BioGaia will be selling its probiotic products under its own management in the UK market. The decision is part of the company’s overall strategy of increasing B2C sales and sales via its own e-commerce solution. BioGaia will launch its entire product portfolio in the British market.
BioGaia’s probiotic products have been available to a limited extent in the UK market for just over eight years, but only through a smaller distributor. As of November 2021, this agreement will be terminated and BioGaia will take over sales. In addition to its own e-commerce, BioGaia’s probiotic products will also be sold on Amazon.co.uk and in selected pharmacy chains both online and offline.
“The UK is a large and attractive market for BioGaia, with many consumers who have good knowledge of probiotics. With our clinically tested probiotic products – something we know that many consumers demand – we have a strong offering for the UK market. Based on our global B2C strategy, it is a natural step for us to start our own distribution in the UK after our own distribution initiative in the Finnish market,” says Isabelle Ducellier, CEO of BioGaia.
In 2020, BioGaia’s Protectis Baby Drops won the prestigious “Best Gut Health Product of the Year” at the Food Matters Live 2020 awards in the UK.
“The UK is a medium-size market for probiotic products. However, when looking at the broader market that includes vitamins and dietary supplements, the market value is roughly 1,5 billion GBP*. I am optimistic about our opportunities for increasing sales in the UK and am looking forward with confidence to developments in the UK market in the near future,” says Isabelle Ducellier.
*Source: Euromonitor 2020 (dietary supplements including vitamins).
For further information, please contact:
Ulrika Engellau, PR & Corporate Communications Manager
Phone: +46 (0)72 235 15 00
Email: ule@biogaia.se
BioGaia is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products with documented health benefits. To date, over 200 articles on clinical trials with BioGaia's probiotic strains have been published. The products are sold by nutrition and pharmaceutical companies in more than 100 countries. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. biogaia.com
Tags: